Therapeutic Advances in Hematology

Papers
(The TQCC of Therapeutic Advances in Hematology is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Monocyte or white blood cell counts and β2 microglobulin predict the durable efficacy of daratumumab with lenalidomide28
The importance of terminal complement inhibition in paroxysmal nocturnal hemoglobinuria27
Prognostic impact of IL7R mutations on acute myeloid leukemia27
BEST study: one-year descriptive follow-up of bevacizumab treatment in hereditary haemorrhagic telangiectasia post-BABH interventional study27
Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine24
Effective engraftment via granulocyte transfusion in pre-engraftment febrile neutropenia following allogeneic hematopoietic stem cell transplantation: granulocyte transfusion as bridge therapy24
Brain iron content and cognitive function in patients with β-thalassemia22
Successful maintenance of a sustained molecular response in CML patients receiving low-dose tyrosine kinase inhibitors21
Treatment of multiple myeloma: What is the impact on T-cell function?20
Role of abatacept in the prevention of graft-versus-host disease: current perspectives19
Macrofocal multiple myeloma in the era of novel agents in China19
A comparison of the effect of three different comorbidity indices on overall survival in patients with chronic myeloid leukemia18
Comparison of eltrombopag and avatrombopag in the treatment of refractory/relapsed aplastic anemia: a single-center retrospective study in China15
Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-cente15
Outcomes and effect of somatic mutations after erythropoiesis stimulating agents in patients with lower-risk myelodysplastic syndromes15
Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma15
The role of surveillance computed tomography in patients with follicular lymphoma13
Real-world usage and effectiveness of recombinant factor IX Fc in haemophilia B from the B-SURE study in France13
Recombinant factor IX Fc prophylaxis reduces pain and increases levels of physical activity, with sustained, long-term improvements in patients with hemophilia B: post hoc analysis of phase III13
Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review13
Safety and efficacy of luspatercept in treating anemia associated with myelodysplastic syndrome with ring sideroblasts in Asian patients who require red blood cell transfusions: a phase II bridging st13
How to translate and implement the current science of gene therapy into haemophilia care?13
Successful rechallenge with Erwinia chrysanthemi asparaginase after pegaspargase-induced hypertriglyceridemia: a case report12
Thanks to Reviewers12
Advancements in minimal residual disease detection: a practical approach using single-cell droplet PCR for comprehensive monitoring in hematological malignancy11
Use and positioning of fostamatinib in the management of primary chronic immune thrombocytopenia: an Italian expert opinion11
Cardiovascular-specific mortality among multiple myeloma patients: a population-based study10
Anemia is associated with long-term exposure to PM2.5 and its components: a large population-based study in Southwest China10
Efficacy and safety of anti-CD38 monoclonal antibodies-based therapy versus standard therapy in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis10
Corrigendum to “Real-world use of recombinant porcine sequence factor VIII in the treatment of acquired hemophilia A: EU PASS”9
Association of CVAI, LAP and SMI with risk of haematological toxicity after immunochemotherapy in patients with DLBCL: a retrospective study9
A new beginning: can omidubicel emerge as the next, viable alternative donor source?9
Mantle cell lymphoma management trends and novel agents: where are we going?9
Non-invasive prenatal testing for fetal Ss, Kidd, and CTL2 blood group prediction by multiplex digital droplet PCR9
Toxicity management strategies for next-generation novel therapeutics in multiple myeloma9
Calculated haemorheological profile and laboratory parameters in new diagnosed multiple myeloma patients: retrospective analysis according to survival8
Between Charybdis and Scylla—an Odyssey in AL amyloidosis: insights and learnings from a narrative review and case report series8
Efficacy of complement inhibitors for patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis8
Efficacy and safety of venetoclax-based regimens for the treatment of relapsed/refractory multiple myeloma: a systemic review and meta-analysis8
Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia8
Interferons in the treatment of myeloproliferative neoplasms8
Superior survival outcome of blinatumomab compared with conventional chemotherapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia: a propensity score–match8
A systematic review and meta-analysis of carfilzomib-associated thrombocytopenia as an adverse event in patients with multiple myeloma8
Assessment of risk factors for acute graft-versus-host disease post-hematopoietic stem cell transplantation: a retrospective study based on a proportional odds model using a nonlinear mixed-eff8
Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors8
Avatrombopag treatment response in patients with immune thrombocytopenia: the REAL-AVA 1.0 study8
Demographics, clinical characteristics, and real-world treatment patterns among patients with beta-thalassemia: a retrospective medical record abstraction study7
Application and investigation of thrombopoiesis-stimulating agents in the treatment of thrombocytopenia7
Prognostic significance of MRD and its correlation with arsenic concentration in pediatric acute promyelocytic leukemia: a retrospective study by SCCLG-APL group7
Single-center experience of venetoclax combined with azacitidine in young patients with newly diagnosed acute myeloid leukemia7
Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOVIDEHA registry7
Antihuman T lymphocyte porcine immunoglobulin combined with cyclosporine as first-line immunosuppressive therapy for severe aplastic anemia in China: a large single-center, 10-year retrospective study7
Circulating HMGB1 is increased in myelodysplastic syndrome but not in other bone marrow failure syndromes: proof-of-concept cross-sectional study7
Current state of CAR-T therapy for T-cell malignancies7
0.045261144638062